NEW YORK (GenomeWeb) – Vermillion said today that CareFirst BlueCross BlueShield (BCBS) has agreed to cover its OVA1 ovarian cancer test.
CareFirst BCBS covers more than 3 million patients in Maryland, Washington DC, and Virginia.
"This is our fourth recent announcement of new managed care contracts as we continue to expand our reach in our key strategic market areas," Valerie Palmieri, Vermillion's president and CEO said in a statement. Most recently, the company signed an agreement in July with Michigan healthcare insurance company Priority Health Managed Benefits.
OVA1 is a proteomic test intended for use in patients with an adnexal mass to determine prior to surgery whether the mass is likely malignant or benign and help physicians decide if a patient should be passed on to a gynecologic oncologist for the procedure.